Unicycive Therapeutics (UNCY) Return on Sales (2022 - 2023)

Unicycive Therapeutics' (UNCY) quarterly Return on Sales came in at 5.74% in Q4 2023, little changed on a QoQ basis from 5.73% in Q3 2023.

Unicycive Therapeutics (UNCY) Return on Sales (2022 - 2023) Analysis & Trends

Unicycive Therapeutics (UNCY) has 2 years of Return on Sales data on file, last reported at 5.74% in Q4 2023.

Quarterly Return on Sales changed N/A year-over-year to 5.74% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 5.74% (changed N/A YoY) and the FY2023 annual result came in at 0.46%, down 20.0% from the prior year.
Return on Sales held at 5.74% in Q4 2023, from 5.73% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.06% in Q3 2022 to a low of 5.74% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Unicycive Therapeutics	151.01 Mn	151.01 Mn	-	-

Download Data